Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?

摘要: One to three per cent of the world’s population has hepatitis C virus (HCV) infection, which is not only a major cause liver disease and cancer but also associated with an increased risk atherosclerosis, despite ostensibly favourable lipid profile. Autoantibodies are frequent in HCV infection emerging evidence shows that autoantibodies could be valuable for cardiovascular (CVD) stratification. This study investigated novel independent biomarker CVD, apolipoprotein A-1 (anti-apoA-1 IgG) lipids patients chronic before, during after direct-acting anti-viral (DAA) therapy. Eighty-nine blinded serum samples from 27 advanced were assayed anti-apoA-1 IgG by ELISA. Pre-treatment viral load correlated high-density lipoprotein cholesterol (HDL-C, r = 0.417; p = 0.042) negatively (apo)B (r = − 0.497; p = 0.013) markers CVD risk, apoB/apoA-1 ratio (r = − 0.490; p = 0.015) triglyceride level (TG)/HDL-C (r = − 0.450; p = 0.031). Fourteen (52%) had detectable pre-treatment; two became undetectable virological cure. Autoantibody-positive sera lower apoA-1 (p = 0.012), HDL-C (p = 0.009) total (p = 0.006) levels. first report presence IgG, some infection. It may induced on surface lipoviral particles. The inversely correlate HDL levels render dysfunctional. Whether these hypothesis-generating findings have clinical implications requires further study.